Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS Topically applied methylene blue dye chromoendoscopy is effective in improving detection of colorectal neoplasia. When combined with a pH- and time-dependent multimatrix structure, a per-oral methylene blue formulation (MB-MMX) can be delivered directly to the colorectal mucosa. METHODS We performed a phase 3 study of 1205 patients scheduled for colorectal cancer screening or surveillance colonoscopies (50-75 years old) at 20 sites in Europe and the United States, from December 2013 through October 2016. Patients were randomly assigned to groups given 200 mg MB-MMX, placebo, or 100 mg MB-MMX (ratio of 2:2:1). The 100-mg MB-MMX group was included for masking purposes. MB-MMX and placebo tablets were administered with a 4-L polyethylene glycol-based bowel preparation. The patients then underwent colonoscopy by an experienced endoscopist with centralized double-reading. The primary endpoint was the proportion of patients with 1 adenoma or carcinoma (adenoma detection rate [ADR]). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for differences in detection between the 200-mg MB-MMX and placebo groups. False-positive (resection rate for non-neoplastic polyps) and adverse events were assessed as secondary endpoints. RESULTS The ADR was higher for the MB-MMX group (273 of 485 patients, 56.29%) than the placebo group (229 of 479 patients, 47.81%) (OR 1.46; 95% CI 1.09-1.96). The proportion of patients with nonpolypoid lesions was higher in the MB-MMX group (213 of 485 patients, 43.92%) than the placebo group (168 of 479 patients, 35.07%) (OR 1.66; 95% CI 1.21-2.26). The proportion of patients with adenomas ≤5 mm was higher in the MB-MMX group (180 of 485 patients, 37.11%) than the placebo group (148 of 479 patients, 30.90%) (OR 1.36; 95% CI 1.01-1.83), but there was no difference between groups in detection of polypoid or larger lesions. The false-positive rate did not differ significantly between groups (83 [23.31%] of 356 patients with non-neoplastic lesions in the MB-MMX vs 97 [29.75%] of 326 patients with non-neoplastic lesions in the placebo group). Overall, 0.7% of patients had severe adverse events but there was no significant difference between groups. CONCLUSIONS In a phase 3 trial of patients undergoing screening or surveillance colonoscopies, we found MB-MMX led to an absolute 8.5% increase in ADR, compared with placebo, without increasing the removal of non-neoplastic lesions. Clinicaltrials.gov no: NCT01694966.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenoma detection rate and risk of colorectal cancer and death
Corley, D. A., Jensen, C. D., Marks, A. R., Zhao, W. K., Lee, J. K., Doubeni, C. A., Zauber, A. G., de Boer, J., Fireman, B. H., Schottinger, J. E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309086 · Cited by 2,270
Long-term colorectal-cancer incidence and mortality after lower endoscopy
Nishihara, R., Wu, K., Lochhead, P., Morikawa, T., Liao, X., Qian, Z. R., Inamura, K., Kim, S. A., Kuchiba, A., Yamauchi, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301969 · Cited by 1,483
Cited by
ACG Clinical Guidelines: Colorectal Cancer Screening 2021
Shaukat, A., Kahi, C. J., Burke, C. A., Rabeneck, L., Sauer, B. G., & Rex, D. K. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001122 · Cited by 853
Strategies for Colorectal Cancer Screening
Ladabaum, U., Dominitz, J. A., Kahi, C., & Schoen, R. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.06.043 · Cited by 696
Efficacy of real-time computer-aided detection of colorectal neoplasia in a randomized trial
Repici, A., Badalamenti, M., Maselli, R., Correale, L., Radaelli, F., Rondonotti, E., Ferrara, E., Spadaccini, M., Alkandari, A., Fugazza, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.062 · Cited by 646
Self-citationKamiński, M., Hassan, C., Bisschops, R., Pohl, J., Pellisé, M., Dekker, E., Ignjatovic-Wilson, A., Hoffman, A., Longcroft-Wheaton, G., Heresbach, D., et al. (2014) · Endoscopy · doi:10.1055/s-0034-1365348 · Cited by 433
Self-citationBisschops, R., East, J. E., Hassan, C., Hazewinkel, Y., Kamiński, M. F., Neumann, H., Pellisé, M., Antonelli, G., Bustamante Balen, M., Coron, E., et al. (2019) · Endoscopy · doi:10.1055/a-1031-7657 · Cited by 340
Self-citation
Metadata
- Authors
- Repici, A., Wallace, M. B., East, J. E., Sharma, P., Ramirez, F. C., Bruining, D. H., Young, M., Gatof, D., Irene (Mimi) Canto, M., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P. D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., Radaelli, F., Bhandari, P., Wilson, A., Early, D., Gupta, N., Vieth, M., Lauwers, G. Y., Rossini, M., & Hassan, C.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 156
- Issue
- 8
- Pages
- 2198-2207.e1
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2913899589
- Cited by
- 84
- References
- 2
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy. https://app.cochat.ai/papers/10.1053/j.gastro.2019.02.001
- The paper
- Repici, A., Wallace, M. B., East, J. E., Sharma, P., Ramirez, F. C., Bruining, D. H., Young, M., Gatof, D., Irene (Mimi) Canto, M., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P. D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., . . . Hassan, C. (2019). Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.02.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.